ChemicalBook > CAS DataBase List > RO-31-7549

RO-31-7549

Product Name
RO-31-7549
CAS No.
125313-65-7
Chemical Name
RO-31-7549
Synonyms
RO-31-7549;RO 31-7549 ACETATE SALT;Bisindolylmaleimide VIII;BISINDOLYLMALEIMIDE VIII ACETATE;BIDINDOLYLMALEIMIDE VIII, ACETETE;Ro-31-7549, Monohydrate - CAS 125313-65-7 - Calbiochem;2-[1-3(AMINOPROPYL)INDOL-3-YL]-3(1-METHYL-1H-INDOL-3-YL)MALEIMIDE, ACETATE;3-(1-(3-Aminopropyl)-1H-indol-3-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione;1H-Pyrrole-2,5-dione, 3-(1-(3-aminopropyl)-1H-indol-3-yl)-4-(1-methyl-1H-indol-3-yl)-
CBNumber
CB1281637
Molecular Formula
C24H22N4O2
Formula Weight
398.46
MOL File
125313-65-7.mol
More
Less

RO-31-7549 Property

storage temp. 
−20°C
solubility 
DMSO: soluble
form 
Red to reddish-orange solid
color 
red to red-orange
More
Less

Safety

WGK Germany 
3
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
557508
Product name
Ro-31-7549, Monohydrate - CAS 125313-65-7 - Calbiochem<br />A cell permeable, reversible, selective protein kinase C (PKC) inhibitor (IC = 158 nM for rat brain PKC) that acts at the ATP binding site of PKC.
Packaging
1mg
Price
$189
Updated
2025/07/31
Usbiological
Product number
044608
Product name
Bisindolylmaleimide VIII acetate
Packaging
1mg
Price
$286
Updated
2021/12/16
More
Less

RO-31-7549 Chemical Properties,Usage,Production

Uses

It is a potent inhibitor of protein kinase C (PKC) activity.

General Description

A cell permeable, reversible, selective protein kinase C (PKC) inhibitor (IC50 = 158 nM for rat brain PKC) that acts at the ATP binding site of PKC. Does not inhibit the tyrosine phosphorylation or the activation of phospholipase Cγ1. Exhibits some degree of PKC isozyme specificity (IC50 = 53 nM for PKCα, 195 nM for PKCβI, 163 nM for PKCβII, 213 nM for PKCγ, and 175 nM for PKCε). Inhibits carbachol-evoked noradrenaline release (IC50 = 600 nM).

Biochem/physiol Actions

Cell permeable: yes

in vivo

Bisindolylmaleimide VIII (100 μg; i.p; every other day for three doses) results in nearly complete tumor regression combined toTRA-8. With Bisindolylmaleimide VIII alone does not induce significant tumor regression[2].

Animal Model:6-8-week-old female NOD/SCID mice[2].
Dosage:100 μg
Administration:i.p.; every other day for three doses
Result:Resulted in nearly complete tumor regression combined toTRA-8.

IC 50

Rat Brain PKC: 158 nM (IC50); PKCα: 53 nM (IC50); PKC-βI: 195 nM (IC50); PKC-βII: 163 nM (IC50); PKCγ: 213 nM (IC50); PKCε: 175 nM (IC50)

RO-31-7549 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

RO-31-7549 Suppliers

Canada 1 China 33 Japan 2 Switzerland 3 United Kingdom 2 United States 5 Global 46
TargetMol Chemicals Inc.
Tel
+1-781-999-5354; +17819995354
Email
marketing@targetmol.com
Country
United States
ProdList
32435
Advantage
58
United States Biological
Tel
--
Fax
--
Email
chemicals@usbio.net
Country
United States
ProdList
6214
Advantage
80
Riedel-de Haen AG
Tel
--
Fax
--
Country
United States
ProdList
6773
Advantage
87
HONEST JOY HOLDINGS LIMITED
Tel
--
Fax
--
Email
sales@honestjoy.cn
Country
United States
ProdList
6675
Advantage
54
EMD Biosciences, Inc.
Tel
--
Fax
--
Email
technical@calbiochem.com
Country
United States
ProdList
6529
Advantage
66

125313-65-7, RO-31-7549Related Search:

Bisindolylmaleimide V RO 31-7549, IMMOBILIZED RO 31-7549 ACETATE 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione 3-Isopropenyl-1-methyl-1H-pyrrole RO-31-7549

  • BISINDOLYLMALEIMIDE VIII ACETATE
  • 1H-Pyrrole-2,5-dione, 3-(1-(3-aminopropyl)-1H-indol-3-yl)-4-(1-methyl-1H-indol-3-yl)-
  • 3-(1-(3-Aminopropyl)-1H-indol-3-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione
  • Bisindolylmaleimide VIII
  • 2-[1-3(AMINOPROPYL)INDOL-3-YL]-3(1-METHYL-1H-INDOL-3-YL)MALEIMIDE, ACETATE
  • RO-31-7549
  • RO 31-7549 ACETATE SALT
  • BIDINDOLYLMALEIMIDE VIII, ACETETE
  • Ro-31-7549, Monohydrate - CAS 125313-65-7 - Calbiochem
  • 125313-65-7
  • C24H22N4O2C2H4O2
  • Amines
  • Aromatics
  • Heterocycles
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Protein Kinase Inhibitors and Activators